Growing a world-class precision medicine industry
Monash Biomedical Imaging is part of the new $71.2 million Australian Precision Medicine Enterprise (APME) facility, which will deliver large-scale development and manufacturing of precision medicines and theranostic radiopharmaceuticals for industry and research. A key feature of the APME project is a high-energy cyclotron with multiple production clean rooms, which will be located on the Monash Biomedical Imaging (MBI) site in Clayton. This strategic co-location will facilitate radiochemistry, PET and SPECT research and clinical use of theranostic (therapeutic and diagnostic) radioisotopes produced on-site. In this webinar, MBI’s Professor Gary Egan and Dr Maggie Aulsebrook will explain how the APME will secure Australia’s supply of critical radiopharmaceuticals, build a globally competitive Australian manufacturing hub, and train scientists and engineers for the Australian workforce. They will cover the APME’s state-of-the-art 30 MeV and 18-24 MeV cyclotrons and radiochemistry facilities, as well as the services that will be accessible to students, scientists, clinical researchers, and pharmaceutical companies in Australia and around the world. The APME is a collaboration between Monash University, Global Medical Solutions Australia, and Telix Pharmaceuticals. Professor Gary Egan is Director of Monash Biomedical Imaging, Director of the ARC Centre of Excellence for Integrative Brain Function and a Distinguished Professor at the Turner Institute for Brain and Mental Health, Monash University. He is also lead investigator of the Victorian Biomedical Imaging Capability, and Deputy Director of the Australian National Imaging Facility. Dr Maggie Aulsebrook obtained her PhD in Chemistry at Monash University and specialises in the development and clinical translation of radiopharmaceuticals. She has led the development of several investigational radiopharmaceuticals for first-in-human application. Maggie leads the Radiochemistry Platform at Monash Biomedical Imaging.
From aura to neuroinflammation: Has imaging resolved the puzzle of migraine pathophysiology?
In this talk I will present data from imaging studies that we have been conducting for the past 20 years trying to shed light on migraine physiopathology, from anatomical and functional MRI to positron emission tomography.
Virtual launch and webinar: Magnetic Particle Imaging at Monash University
Magnetic Particle Imaging (MPI) is a new non-invasive imaging technique with significantly increased sensitivity over MRI and faster acquisition times than PET and MRI. The MPI capability at the Alfred Research Alliance - Monash Biomedical Imaging site in Melbourne, Australia, is the world’s first MPI system with Computed Tomography (CT) and Hyperthermia capabilities. It provides unique capabilities that open the door to cutting-edge opportunities for interdisciplinary projects in medical research, chemistry and biotechnology. The webinar will involve: * official launch of Magnetic Particle Imaging at Monash University * the MPI system supplier, Magnetic Insight, discussing the world first technology and its potential * presentations from key researchers outlining MPI applications and the benefits of utilising the technology.